Navigation Links
Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Date:2/20/2008

licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements regarding Sunesis' collaboration with J&JPRD and the potential for Sunesis to receive additional milestone payments and royalties from J&JPRD. These forward-looking statements involve risks and uncertainties. Sunesis' actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that J&JPRD's research and development activities with respect to collaboration compounds could be halted or delayed for various reasons or that there may never be sales from a resulting product. Sunesis may never receive any additional milestone payments or royalties from J&JPRD in connection with this collaboration. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year ended December 31, 2006, Sunesis' most recent quarterly report on Form 10-Q and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
2. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
5. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
6. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
7. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
8. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
...s (CTI),(Nasdaq and MTA: CTIC) announced today tha...hareholders on February 27, 2009 in lieu of the Sp...o take place on February 6, 2009.,Shareholders of ...9, the,record date established by the Board of Dir...eting. Updated proxy materials, including an updat...
... (Nasdaq: NVAX ) a clinical-stage vaccine compan...d Chief Medical Officer, will be presenting at the...nce on January 26, 2009 at the Grand Hyatt in Wash...cus Session ,What benefits are single-use technolo...ns providing in practice, and will be speaking to ...
... with Acute Spinal Cord Injury , Geron Corpora...d and Drug,Administration (FDA) has granted cleara...) application for the clinical trial of GRNOPC1 in...ance enables Geron to move forward with,the world,...l-based therapy,in man. , Geron plans to initi...
Other Biology Technology:Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 3MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy 2
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Research is vital to a cleaner, greener, low carbon future 2By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 1By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 1Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 4Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 5Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 1Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 3
...lts with obstructive sleep apnea benefit significa...e airway pressure (CPAP), a device to improve brea...rted by the National Heart, Lung, and Blood Instit...This is the first study to identify the nightly du...for daytime alertness and functioning. , Research...
...anotubes are nature’s smallest candles. , These ti...y are so small that it takes about 100,000 laid si...r. In the last five years, scientists have discove.... That is, they glow when they are bathed in light... in spots. Others glow all over. , Until now, th...
...alists associated with the Neuroscience Institute ...y Hospital say the ability to incorporate—in real ...g room can improve the functional abilities of pat...st James Leach, MD, and his UC colleagues are amon...onal magnetic resonance imaging (MRI) and “diffusi...
Other Biology News:Longer treatment benefits sleep apnea patients 2Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3Dual-imaging technique useful before -- and during -- brain surgery 2
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer* from Molecular Probes (Invitrogen)
ER-beta Fluorescence polarization Assay Kit from Invitrogen
GIBCO MEM Non-Essential Amino Acids Solution 10 mM (100X), liquid from Invitrogen
...rains are K-12 derivatives that have mutations in ...one reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielde... even though overall expression levels were simila...
Biology Products: